Giannatempo, Patrizia
Mayo Clinic
Fondazione IRCCS Istituto Nazionale dei Tumori
Citations 1
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer
Antonelli, Luca , Ardizzone, Davide, Tachibana, Isamu , Adra, Nabil , Cary, Clint , Sexton, Wade J. , Daneshmand, Siamak , Franza, Andrea , Heidenreich, Axel , Paffenholz, Pia , Saoud, Ragheed , Eggener, Scott E. , Oswald, Nathaniel W., Olson, Kathleen, Tryakin, A. , Javaud, Christophe, Cazzaniga, Walter , Nicol, David , Gerdtsson, Axel , Tandstad, Torgrim , Fizazi, Karim , Sexton, Wade J , Bagrodia, Aditya , Daneshmand, Siamak , Nazzani, Sebastiano , Franza, Andrea , Heidenreich, Axel , Saoud, Ragheed , Eggener, Scott , Oswald, Nathaniel, Tryakin, Alexey , Fedyanin, Mikhail , Cazzaniga, Walter , Gerdtsson, Axel , Fizazi, Karim , Fankhauser, Christian Daniel , Hugar, Lee A. , Mego, Michal , Nicolai, Nicola , Giannatempo, Patrizia , Ho, Matthew, Olson, Kathleen, Naoun, Natacha
Journal of Clinical Oncology | September 1, 2023 | Volume: 41 | Issue: 34 | Pages: 5296-5305
What is the role of pcRPLND in men with retroperitoneal vital cancer after first-line chemotherapy? This question arises because of the potential predictive value of miR371 in identifying residual cancer even before pcRPLND! @cdfankhauser shared data within a multicenter cohort study redefining future practice in the miR371 era.